Abstract
Objective: To review and analyze the pathophysiology, diagnosis and management of patients with coagulation disorders due to COVID 19. Bibliographic review: COVID-19 causes a profound inflammatory response in the human body, which results in several procoagulant mechanisms, which may be considered an endotheliopathy that results in increased platelet activation and hypercoagulability, leading to prothrombotic clinical manifestations associated with the infection. Typical findings in COVID-19-associated coagulopathy show an increase in the concentration of D-dimer, a modest decrease in platelet count, and a prolongation of the prothrombin time. In patients with mild or moderate severity, adequate hydration, movement and post-discharge prophylaxis are recommended. This prophylaxis consists of monitoring the thrombotic risk when necessary. Thus, it should be individualized by analyzing the patient's age, existence of reduced mobility condition, previous VTE, BMI >30 and active cancer or other prothrombotic comorbidities. Fina: The new coronavirus causes respiratory disorders in addition to several systemic manifestations such as coagulopathies. Thus, with adequate screening and prophylactic measures, it is possible to reduce the chances of serious complications and improve patient care.